PURPOSE: To describe the features of carcinoembryonic antigen (CEA) that are important
for its use in vaccination approaches and review the clinical experience with therapeutic …

Advances in molecular biology and immunology have renewed interest in the development
of vaccines for the treatment or prevention of cancer. Research over the past 10 years has …

Carcinoembryonic antigen (CEA), the first tumor-associated antigen to be described, was
cloned in 1987 and is expressed on nearly 50% of all human tumors. The identification of T …

Carcinoembryonic antigen (CEA), a glycosylated protein of MW 180 kDa, is overexpressed
in a wide range of human carcinomas, including colorectal, gastric, pancreatic, non-small …

Carcinoembryonic antigen (CEA) is a glycoprotein that is normally expressed in certain parts
of the body and commonly overexpressed in most carcinomas of the colon, rectum, breast …

The vaccine approach to cancer therapy is still in the early stages. Since any immune
response has a limited capacity, immunotherapeutic manipulations to destroy tumor will …

The generation of cytotoxic effector T cells requires delivery of two signals, one derived from
a specific antigenic epitope and one from a costimulatory molecule. A phase I clinical trial …

Coordinated presentation of antigen and costimulatory molecules has been shown to result
in the induction of an antigen-specific T-cell response rather than the development of …

Carcinoembryonic antigen (CEA) is a well-characterized oncofetal glycoprotein whose
overexpression by human adenocarcinomas has been a target for cancer immunotherapy …

Human carcinoembryonic antigen (CEA) is an oncofetal glycoprotein overexpression of
which by gastrointestinal carcinomas is well known. Expression of CEA in head and neck …